Reklāma
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
556 days ago
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
811 days ago
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
838 days ago
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
910 days ago
Sensex, Nifty Give Up Early Gains
Indian shares ended slightly lower on Monday, failing to hold early gains due to uncertainty surrounding U.S. tariffs and signs of deepening deflationary pressures in China.
RTTNews
|
4h 18min ago
CAC 40 Modestly Lower In Cautious Trade
French stocks are exhibiting weakness Monday morning with investors making cautious moves amid concerns about growth and international trade due to continued uncertainty about the policies of the Trump Administration.
RTTNews
|
4h 21min ago
DAX Down 0.4% As Stocks Retreat After Positive Start
German stocks retreated after a positive start Monday morning amid concerns about the outlook for global economic growth following recent weak economic data from the U.S. and China, and the potential impact of U.S. tariffs.
RTTNews
|
4h 52min ago
European Shares Little Changed In Cautious Trade
European shares were largely steady on Monday after a week of high volatility on concerns about an escalating global trade war and its potential impact on global economic growth.
RTTNews
|
5h 41min ago
